Significant Ownership of Clearline Capital LP
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Clearline Capital LP focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- Marc Majzner - Limited Partner
- Manager location
- New York, NY
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Clearline Capital LP and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
CIK context first
Continue from Clearline Capital LP
Significant Ownership of Clearline Capital LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| HRTX | HERON THERAPEUTICS, INC. /DE/ | Common Stock, par value $0.01 per share | 6.7% | $18,108,154 | +$3,733,614 | 12,235,239 | +26% | Clearline Capital LP | 31 Dec 2025 |
| XPER | Xperi Inc. | Common Stock (par value $0.001 per share) | 6.4% | $17,787,867 | 2,949,895 | Clearline Capital LP | 31 Dec 2025 | ||
| TXMD | TherapeuticsMD, Inc. | Common Stock, par value $0.001 per share | 5.5% | $705,096 | 635,222 | Clearline Capital LP | 31 Dec 2024 | ||
| MX | MAGNACHIP SEMICONDUCTOR Corp | Common Stock, par value $0.01 per share | 4.1% | $3,725,642 | -$1,119,807 | 1,461,036 | -23% | Clearline Capital LP | 31 Dec 2025 |
Schedules 13D/G Reported by Clearline Capital LP:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.